Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~* Female, aged 18 to 45 years, inclusive~* Have moderate to severe pelvic pain due to endometriosis~* Have been surgically (laparoscopy) diagnosed with endometriosis within the last 5 years and have recurrent or persistent endometriosis symptoms~* Have regular menstrual cycle (23-33 day)~* Agree to use two forms of non-hormonal contraception during the study~Exclusion Criteria:~* Received a Gonadotropin-releasing hormone (GnRH) agonist, GnRH antagonist, danazol, or have received any of these agents within 6 months of the start of screening.~* Received subcutaneous medroxyprogesterone acetate (DMPA-SC) or intramuscular (i.m.) medroxyprogesterone acetate (DMPA-IM), or have received either of these agents within 3 months of the start of screening.~* Are currently using hormonal contraception or other forms of hormonal therapy or received such treatment within the last month~* Have had surgery for endometriosis within the last month~* Are using systemic steroids on a chronic or regular basis within 3 months~* Have uterine fibroids or other pelvic lesions ≥ 3 cm in diameter~* Have had a hysterectomy or oophorectomy~* Have pelvic pain that is not caused by endometriosis~* Have unstable medical condition or chronic disease~* Have been pregnant within the last 6 months and is currently breast feeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
- Elagolix 150 mg (Type: EXPERIMENTAL): Participants received elagolix 150 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg for an additional 12 weeks.
- Elagolix 250 mg (Type: EXPERIMENTAL): Participants received elagolix 250 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
- Leuprorelin (Type: OTHER): Participants received placebo tablets once a day and leuprorelin acetate 1-month depot 3.75 mg intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).